Authors

Latest:

Dr. Hamlin on the Significance of the ZUMA-I Trial

Paul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.

Paul A. Hamlin, MD, MSKCC

Paul B. Chapman, MD

Latest:

Dr. Chapman on Targeted Treatments for Non-Traditional Mutations in Melanoma

Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Paul B. Jacobsen, PhD

Latest:

Paul Jacobsen Discusses Survivorship Care Plans

Paul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans

Paul Baas, MD

Latest:

Dr. Baas on Next Steps in the Treatment of Mesothelioma

Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

Paul Baas, MD, PhD

Latest:

Dr. Baas on Immunotherapy in Mesothelioma Subpopulations

Paul Baas, MD, PhD, discusses the benefits of immunotherapy in subpopulations of patients with mesothelioma.

Paul Barr, MD

Latest:

Dr. Barr on the Implications of the Long-Term Results of the RESONATE-2 Trial in CLL

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Paul Beresford, PhD

Latest:

Beresford Discusses Using VeriStrat With Immunotherapies

Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

Paul Chapman, MD

Latest:

Dr. Chapman on BRAF/MEK Combination for Melanoma

Dr. Paul Chapman, from Memorial Sloan-Kettering Cancer Center, on Combining BRAF and MEK Inhibitors for Advanced Melanoma

Paul D. Nathan, MBBS, PhD, FRCP

Paul Nathan, MBBS, PhD, MRCP, is a consultant medical oncologist at The Mount Vernon Cancer Centre in the United Kingdom.

Latest:

Dr Nathan on the Mechanism of Action of Roginolisib in Metastatic Uveal Melanoma

Paul Nathan, MBBS, PhD, MRCP, describes the mechanism of action of roginolisib and its ongoing evaluation in metastatic uveal melanoma.

Paul Dent, PhD

Latest:

VCU Explores Novel Combos for Solid Tumors

Studies conducted at VCU Massey Cancer Center in Richmond, Virginia, over the past 7 years have developed the therapeutic combination of pemetrexed and sorafenib (Nexavar) from the bench to the bedside, and now into phase II clinical trial evaluation.

Paul E. Oberstein, MD

Paul E. Oberstein, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine; service chief of the Gastrointestinal Medical Oncology Program; and assistant director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center

Latest:

Clinical Trial and Real-World Data With NALIRIFOX Shape the Future of Pancreatic Cancer Care: With Tara E. Seery, MD; Paul E. Oberstein, MD; and Priyadarshini Pathak, MBBS

Drs Seery, Oberstein, and Pathak discuss data from the NAPOLI 3 trial of NALIRIFOX vs nab-paclitaxel and gemcitabine in treatment-naive pancreatic cancer.

Paul E. Oberstein, MD, NYU Langone Perlmutter Cancer Center

Paul Eber, MD

Latest:

Dr. Eber Discusses Patient Selection for Cytoreductive Nephrectomy in mRCC

Paul Eber, MD, urologist, The Conrad Pearson Clinic, discusses patient selection for cytoreductive nephrectomy in the treatment of metastatic renal cell carcinoma.

Paul G. Corn, MD, PhD

Latest:

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

Paul G. Richardson, MD

Paul G. Richardson, MD, is the RJ Corman Professor of Medicine at Harvard Medical School and the clinical program leader and director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, both in Boston, Massachusetts.

Latest:

Dr Richardson on Optimal Treatment Strategies for 1q–Amplified Multiple Myeloma

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

Paul G. Richardson, MD, Harvard Medical School

Paul H. Sugarbaker, MD, FACS, FRCS

Latest:

Dr. Sugarbaker on Perioperative Chemotherapy in Gastrointestinal Cancer

Paul H. Sugarbaker, MD, FACS, FRCS, chief of the peritoneal surface malignancy program and director of the Center for Gastrointestinal Malignancies at MedStar Washington Hospital Center, discusses the use of perioperative chemotherapy in the treatment of patients with gastrointestinal (GI) cancer.

Paul Harari, MD, FASCO

Latest:

Dr. Harari on Upright Proton Radiation Therapy in Cancer Care

Paul M. Harari, MD, discusses the new upright delivery method of proton radiation therapy in cancer care.

Paul J. Hesketh, MD

Latest:

Dr. Hesketh on Developing Guidelines and Protocols

Dr. Paul J. Hesketh, from Lahey Clinic Medical Center, on Developing Guidelines and Protocols